MacroChem CEO to Participate in Industry Panel on Sexual Dysfunction and Hormone Therapies Annual BIO CEO & Investor Conference to be Held February 23-24 in NYC LEXINGTON, Mass., Feb. 22 /PRNewswire-FirstCall/ -- MacroChem Corporation (NasdaqSC: MCHM), a specialty pharmaceutical company, has announced that Robert J. DeLuccia, president and chief executive officer, will participate in an industry panel titled Advances in Sexual Dysfunction and Hormone Therapies at the BIO CEO & Investor Conference at 9:30 a.m. on February 24, 2005 at the Waldorf-Astoria Hotel in New York City. As part of the discussion, Mr. DeLuccia will review the company's product in clinical development for treating male hypogonadism -- Opterone(R), a topical testosterone cream containing MacroChem's patented drug-absorption enhancer, SEPA(R). MacroChem is currently conducting a bioavailability study of Opterone, which it expects to announce results later this year. The BIO CEO & Investor Conference is hosted by the Biotechnology Industry Organization, (BIO), which represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. At this year's conference, investors and corporate managers will attend 24 focus sessions addressing important therapeutic and technology topics, and hear 120 individual company presentations. About MacroChem MacroChem is a specialty pharmaceutical company that innovates, develops and commercializes pharmaceuticals administered in novel ways, to treat important medical conditions. MacroChem is developing two products containing its patented enhancer, SEPA(R): Opterone(R), a SEPA-enhanced topical testosterone treatment for male hypogonadism; and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis. Visit our website at: http://www.macrochem.com/. Forward-Looking Statements With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Visit our web site at: http://www.macrochem.com/. Investor Contact: Bernard Patriacca - VP/CFO (781) 862-4003 Media Contact: Donna LaVoie (LaVoie Group) (781) 596-0200 x103 DATASOURCE: MacroChem Corporation CONTACT: Investor Contact: Bernard Patriacca, VP/CFO of MacroChem, +1-781-862-4003; or Media Contact: Donna LaVoie of LaVoie Group, +1-781-596-0200 ext. 103 Web site: http://www.macrochem.com/

Copyright